<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01460069</url>
  </required_header>
  <id_info>
    <org_study_id>2011-000571-13</org_study_id>
    <nct_id>NCT01460069</nct_id>
  </id_info>
  <brief_title>The Effect of Glucagon Like Peptide (GLP)-1 in Psoriasis</brief_title>
  <official_title>The Effect of GLP-1 in Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Annesofie Faurschou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to investigate the effect of the GLP-1 analogue Victoza® on
      psoriasis in a double-blinded, randomized placebo-controlled clinical trial.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PASI (psoriasis area and severity index)</measure>
    <time_frame>Baseline and after 2 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>DLQI (dermatology life quality index)</measure>
    <time_frame>Baseline and after 2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body mass index</measure>
    <time_frame>Baseline and after 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP</measure>
    <time_frame>Baseline and after 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin biopsies</measure>
    <time_frame>Baseline and after 2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Victoza treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo pens contain saline and are administered in the same way and volume as Victoza. The placebo pens are specially prepared for this study and will be used in the study only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>Victoza® is supplied in pens for injection containing 18 mg of the GLP-1 agonist liraglutide in 3 mL sterile water with disodiumphosphate and propylenglycol, and phenol for conservation (pH 8.15). Commercial pens will be used and the information given in the packaging will be applicable. The initial daily dose will be 0.6 mg for one week, 1.2 mg the following week and then 1.8 mg for the remaining treatment period. The injection is administered once daily in the morning. The maximal plasma concentration is reached 8-12 hours after subcutaneous injection. The half-life in plasma is approximately 13 hours. The duration of effect is 24 hours.</description>
    <arm_group_label>Victoza treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo pens contain saline and are administered in the same way and volume as (liraglutide) Victoza. The placebo pens are specially prepared for this study and will be used in the study only.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Caucasians above 18 years of age

          -  Plaque psoriasis

          -  PASI score &gt;10

          -  No treatment or stable treatment of psoriasis during at least 3 months before
             inclusion

          -  Steady weight through 3 months with a body mass index (BMI) above 27 kg/m2

          -  Normal blood pressure

          -  Spiral or hormonal birth control for fertile women during the entire treatment period
             and at least 3 days after the end of the treatment period (~5 times the plasma
             half-life)

        Exclusion Criteria:

          -  Psoriasis arthritis

          -  Fasting plasma glucose &gt; 7.5 mmol/L or HbA1c &gt; 7.5%

          -  Type 1 diabetes

          -  Treatment for type 2 diabetes with GLP-1-based medicine (DDP-4-inhibitors or
             GLP-1-receptor-agonists)

          -  Heart failure, NYHA class III-IV

          -  Uraemia, end-stage renal disease, or any other cause of impaired renal function with
             s-creatinine &gt;150 µM and/or albuminuria

          -  Liver disease (alanine amino transferase (ALAT) and/or aspartate amino transferase
             (ASAT) &gt;2 x upper normal serum levels)

          -  Anaemia

          -  Acute or chronic pancreatitis

          -  Struma or thyroid cancer

          -  Pregnancy or breast feeding

          -  Inability to complete the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AnneSofie Faurschou, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gentofte Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gentofte Hospital</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2011</study_first_submitted>
  <study_first_submitted_qc>October 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2011</study_first_posted>
  <last_update_submitted>June 19, 2013</last_update_submitted>
  <last_update_submitted_qc>June 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Annesofie Faurschou</investigator_full_name>
    <investigator_title>MD PhD - Resident in dermatology</investigator_title>
  </responsible_party>
  <keyword>psoriasis</keyword>
  <keyword>liraglutide</keyword>
  <keyword>morbidity</keyword>
  <keyword>PASI</keyword>
  <keyword>DLQI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

